International Anal Neoplasia Society's consensus guidelines for anal cancer screening

Elizabeth A. Stier, Megan A. Clarke, Ashish A. Deshmukh, Nicolas Wentzensen, Yuxin Liu, I. Mary Poynten, Eugenio Nelson Cavallari, Valeria Fink, Luis F. Barroso, Gary M. Clifford, Tamzin Cuming, Stephen E. Goldstone, Richard J. Hillman, Isabela Rosa-Cunha, Luciana La Rosa, Joel M. Palefsky, Rosalyn Plotzker, Jennifer M. Roberts, Naomi Jay

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The International Anal Neoplasia Society (IANS) developed consensus guidelines to inform anal cancer screening use among various high-risk groups. Anal cancer incidence estimates by age among risk groups provided the basis to identify risk thresholds to recommend screening. Guided by risk thresholds, screening initiation at age 35 years was recommended for men who have sex with men (MSM) and transgender women (TW) with HIV. For other people with HIV and MSM and TW not with HIV, screening initiation at age 45 years was recommended. For solid organ transplant recipients, screening initiation beginning from 10 years post-transplant was recommended. For persons with a history of vulvar precancer or cancer, screening initiation was recommended starting within 1 year of diagnosis of vulvar precancer or cancer. Persons aged ≥45 years with a history of cervical/vaginal HSIL or cancer, perianal warts, persistent (>1 year) cervical HPV16, or autoimmune conditions could be considered for screening with shared decision-making, provided there is adequate capacity to perform diagnostic procedures (high-resolution anoscopy [HRA]). Anal cytology, high-risk (hr) human papillomavirus (HPV) testing (including genotyping for HPV16), and hrHPV-cytology co-testing are different strategies currently used for anal cancer screening that show acceptable performance. Thresholds for referral for HRA or follow-up screening tests are delineated. These recommendations from IANS provide the basis to inform management of abnormal screening results, considering currently available screening tools. These guidelines provide a pivotal foundation to help generate consensus among providers and inform the introduction and implementation of risk-targeted screening for anal cancer prevention.

Original languageEnglish
Pages (from-to)1694-1702
Number of pages9
JournalInternational Journal of Cancer
Volume154
Issue number10
DOIs
StateAccepted/In press - 2024

Keywords

  • anal HPV
  • anal cancer
  • anal cancer screening
  • anal cytology

Fingerprint

Dive into the research topics of 'International Anal Neoplasia Society's consensus guidelines for anal cancer screening'. Together they form a unique fingerprint.

Cite this